IMRN

Immuron Ltd

• PUBT·05/14 20:02

  Immuron files Form 3 for Chief Commercial Officer Flavio Palumbo

• PUBT·05/14 20:02

  Immuron files Form 3 as director Daniel Jude Pollock reports beneficial ownership

• TipRanks·05/08 10:34

  Immuron Showcases Oral Antibody Portfolio at Emerging Growth Conference

• PUBT·05/04 22:45

  Immuron files Form 3 for Chairman Paul Gerard Brennan initial beneficial ownership statement

• PUBT·04/30 10:17

  Immuron CEO Lydeamore to present at Emerging Growth Conference

• PUBT·04/29 20:03

  Immuron files Form 3 for Chief Scientific Officer Jerry Kanellos

• PUBT·04/29 20:01

  Immuron files Form 3 for CFO Laurita Aaron James initial beneficial ownership statement

• PUBT·04/29 20:01

  Immuron files initial beneficial ownership statement for director Jeannette Anne Joughin

• PUBT·04/29 20:01

  Immuron CEO Steven Lydeamore files initial beneficial ownership statement

• PUBT·04/29 20:00

  Immuron files Form 3 as director Ravi Savarirayan reports beneficial ownership

• PUBT·04/22 13:12

  Emerging Growth Research raises Immuron price target to $4, keeps Buy-Extended rating

• Seeking Alpha·04/17 11:34

  Immuron Q3 sales rise 16% to A$1.5M

• PUBT·04/17 10:01

  Immuron Q3 sales rise 16% to AUD 1.5 million

• Benzinga·04/10 12:05

  12 Health Care Stocks Moving In Friday's Pre-Market Session

• Reuters·03/05 16:05

  Emerging Growth Research reiterates Buy-Extended on Immuron with $3.90 price target